Function Health, the Texas-based startup that sells direct-to-consumer lab testing and full-body imaging, has secured $450 million in non-dilutive growth financing from General Catalyst’s Customer Value Fund. The round, announced in early August 2026, arrives just eight months after the company closed a $298 million Series B, and it pushes Function’s total capital raised past $800 million across equity and non-dilutive financing combined.
What the Money Buys
Unlike a traditional venture round, General Catalyst’s Customer Value Fund ties capital to customer growth rather than equity dilution, letting Function borrow against future membership revenue to fund expansion. The company runs more than 160 biomarker laboratory panels and offers MRI and CT imaging aimed at catching cancer, aneurysms, strokes and other conditions early, delivered through a network of over 200 physical locations across the United States. Function says the new capital will fund further geographic expansion and deepen its AI analytics stack.
The Medical Intelligence Lab
At the center of Function’s pitch is what it calls the Medical Intelligence Lab, or MI Lab, a proprietary AI model that ingests a user’s lab results, imaging and health history and converts them into a personalized risk profile. The system is designed to flag early warning signs that a single blood panel or scan, read in isolation, might miss, then route users toward targeted supplementation or lifestyle changes. Function has been layering that AI model on top of a rapidly consolidating set of acquisitions.
A Buying Spree Behind the AI Push
In the second quarter of 2026, Function acquired Getlabs, a nationwide mobile blood-draw network that lets members skip the clinic visit entirely, and SuppCo, a dietary supplement tracking platform that closes the loop between a diagnosed deficiency and a recommended product. Those deals followed Function’s earlier acquisition of Ezra, an AI-driven full-body MRI scanning company, which now anchors the imaging side of the business. Together, the acquisitions let Function control the entire pipeline, from sample collection to AI interpretation to a purchasable follow-up action.
How We Got Here
Function launched into a consumer health landscape already crowded with wearables and direct-to-consumer testing companies, but it distinguished itself by bundling dozens of lab markers into a single annual membership and layering software on top to explain results in plain language. The approach found an audience among consumers frustrated by short primary-care visits and insurance-gated testing, and it has attracted a wave of celebrity and influencer endorsement that fueled early growth. The $298 million Series B eight months ago already signaled investor appetite; the new $450 million round suggests General Catalyst sees enough recurring membership revenue to justify a debt-like structure instead of another dilutive raise.
The Skeptics’ Case
Critics of the direct-to-consumer testing model, including some physician groups, warn that broad biomarker panels and full-body scans can generate false positives that trigger unnecessary follow-up procedures, anxiety and cost, without solid evidence that population-wide early screening improves outcomes for healthy, asymptomatic people. Traditional preventive-care guidelines from bodies like the U.S. Preventive Services Task Force are far more conservative about which tests to run and how often, precisely because over-testing carries its own harms. Function counters that its AI-driven risk stratification is designed to reduce noise rather than add to it, but independent, peer-reviewed outcome data on whether its members end up healthier remains limited.
What It Means Next
The deal signals that investors are betting AI-driven interpretation, not just cheaper lab access, is what differentiates the next generation of consumer health companies. If Function’s MI Lab model can demonstrably catch disease earlier at scale, it could pressure traditional primary care and insurers to adopt similar AI triage tools. If the false-positive concerns prove founded, the same funding wave could accelerate calls for tighter regulation of direct-to-consumer AI health scoring before it reaches millions more subscribers.
